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Despite local therapy with curative intent, approximately 30% of men suﬀer from biochemical relapse. Though some of these PSA
relapses are not life threatening, many men eventually progress to metastatic disease and die of prostate cancer. Local therapy is an
option for some men, but many have progression of disease following local salvage attempts. One signiﬁcant issue in this setting
is the lack of reliable imaging biomarkers to guide the use of local salvage therapy, as the likely reason for a low cure rate is the
presenceofundetectedmicrometastaticdiseaseoutsideoftheprostate/prostatebed.Androgendeprivationtherapyisacornerstone
of therapy in the salvage setting. While subsets may beneﬁt in terms of delay in time to metastatic disease and/or death, research is
ongoing to improve salvage systemic therapy. Prostate-speciﬁc membrane antigen (PSMA) is highly overexpressed by the majority
of prostate cancers. While initial methods of exploiting PSMA’s high and selective expression were suboptimal, additional work in
both imaging and therapeutics is progressing. Salvage therapy and imaging modalities in this setting are brieﬂy reviewed, and the
rationale for PSMA-based systemic salvage radioimmunotherapy is described.
1. Prostate-SpeciﬁcAntigen and
Biochemical Relapse
Clinically localized prostate cancer (PC) may have a variable,
often protracted course from ﬁrst diagnosis to metastasis
[1, 2]. Despite recent controversies, prostate-speciﬁc antigen
(PSA) has not only revolutionized diagnosis but is also
used to monitor disease recurrence after primary treatment
options such as radical prostatectomy (RP) or local deﬁnitive
radiotherapy (RT). An important aspect of monitoring is
the concept of biochemical recurrence (BCR) which can be
deﬁned within the framework of PSA. A primary deﬁnition
had proven elusive as there are considerable diﬀerences
between the primary therapies in regards to their PSA
kinetics [3]. Following prostatectomy, absolute PSA values
of 0.2–0.4ng/mL are commonly used to deﬁne BCR, with
a PSA of 0.4ng/mL followed by another increase suggested
for inclusion in clinical trials for men with BCR following
RP [4, 5]. In the post-RT setting, an increase of 2ng/mL
from the patients’ post-RT nadir is used as the marker for
recurrent/persistent disease (biochemical failure) [6].
In many parts of the world, the majority of men
diagnosed with PC are usually well suited for local curative
attempts with RP or RT. In this population it has been shown
thatBCRoccursin12–42%[7]and22–69%[8],respectively,
overall approximating 30% of patients treated with local2 Advances in Urology
therapy for curative intent [5, 9, 10]. In the United States
alone, it is estimated that approximately 50,000 patients are
diagnosed with BCR annually [4, 11].
2. Salvage Therapy: Local Options
Once these patients experience BCR, the decision to start
secondary or salvage therapy is a process for which may be
as complicated as the decision about primary therapy. As at
initial diagnosis, the range of outcomes after BCR is variable,
with some men progressing to overt metastatic disease and
death despite therapy and others dying of other causes even
without further PC intervention [12]. As a concept akin to
other solid tumors, those with local recurrence might be
c u r e dwi t hl o c a lt h e ra p y;s o m ewi t hs y s t e m i cr e c u rr e n c em a y
beneﬁt from systemic therapy, though as with other solid
tumors in general, only those with local recurrence tend to
be cured with salvage therapy. There are many options that
include salvage RP, brachytherapy, external beam radiation
therapy, cryotherapy, androgen deprivation therapy (ADT),
or a combination of these modalities.
For those with BCR following radiation therapy, salvage
radical prostatectomy (SRP) after primary radiotherapy
can oﬀer an eﬀective management option. Eastham and
colleagues studied 146 patients who underwent SRP for
biopsy-proven local recurrence of PC [13]. In this study
BCR was deﬁned as a serum PSA of 0.2ng/mL or higher
or the initiation of androgen deprivation therapy after
radiotherapy. Over a period of 5 years the recurrence-free
probability was 54%, and only one patient experienced a
clinical local recurrence, with a 5-year cumulative incidence
of death from PC of 4%. As all of the prior reported
experience was retrospective, the Cancer and Leukemia
Group B (CALGB) performed a multicenter prospective
study of SRP in patients who had BCR after radiotherapy.
In this study of 41 patients, the 5-year biochemical-free
survival was 55% and overall survival (OS) was 85% [14].
Thetime toﬁrstincontinent-free ratesat3,6,and12months
after surgery were 90%, 18%, and 9%, and time to ﬁrst
erectile dysfunction-free rates following SRP at 3, 6, and 12
months were 87%, 25%, and 14%. Despite these potentially
encouraging eﬃcacy results, SP is currently reserved for a
highly select population based upon a number of factors,
including real and/or perceived toxicity.
Salvage cryotherapy is an option which some see as less
invasive approach to surgery with fewer side eﬀects in the
absence of prospective randomized studies. A retrospective
analysis examined 76 patients over a 10-year period with a
mean Gleason score of 7, who had prostate cryotherapy as
salvage therapy before January 1999. At the end of this study,
43 of 76 men (56.6%) were still alive; 33 men (43.4%) had
died but only 13.2% from prostate cancer and 22.4% from
noncancerous causes, and 6.6% died from unknown causes
[15]. A pooled analysis of salvage cryoablation demonstrated
54.5%5-yearactuarialbiochemicaldisease-freesurvivalwith
an incontinence rate of 4.4% and rectal ﬁstula rate of 1.2%
[16]. These and other investigators have concluded that
cryosurgeryissafeandeﬀectivetreatmentinselectedpatients
in whom radiation therapy fails [15–17]. Further study is
necessary, including improvement and standardization of
technique.
One option commonly oﬀered to patients with BCR after
primary RP is salvage radiation therapy (SRT). Most of the
available data comes from retrospective series. Stephenson
et al. analyzed data from 17 tertiary care centers, evaluating
1540 patients. The six-year progression-free probability was
32% overall, 48% for patients with a pre-SRT PSA less
than or equal to 0.5, 40% with a PSA > 0.5–1, 28% for
patients with a PSA 1–1.5, and 18% for PSA greater than
1.5. These ﬁndings suggest that delivering SRT at the earliest
sign of recurrence, when the PSA is low, is optimal, as
nearly half of patients may have a long-term PSA response,
including some with other unfavorable prognostic factors,
including a PSA doubling time of 10 months or less or with
poorly diﬀerentiated (Gleason 8–10) histology. A nomogram
is available utilizing independently signiﬁcant variables,
includingPSAlevelbeforeSRT,prostatectomyGleasonscore,
PSA doubling time, surgical margins, androgen-deprivation
therapy before or during RT therapy, and lymph node
metastasis [18].
A retrospective review from Johns Hopkins included 635
men who previously underwent RP and were subsequently
observed (63%), underwent SRT (25%), or SRT + hormonal
therapy (12%) for either a biochemical or local recurrence.
SRT was associated with a threefold increase in prostate
cancer-speciﬁc survival (CSS) compared to those not treated
with SRT (HR 0.32, P<0.001). The addition of hormonal
therapy did not improve CSS. Without long-term followup
this beneﬁt in CSS was limited to those with a doubling
time of less than 6 months and persisted after adjustment
for other prognostic factors. SRT delivered greater than two
years after recurrence or, for those men whose PSA never
became undetectable after RP, did not result in improvement
in CSS at the time of analysis [19].
Although there are limitations in the evaluation of
retrospective data, these reports provide solid evidence for
the beneﬁt of early SRT. Important factors to consider in
determining the need for SRT include preoperative and pre-
RT PSA, postrecurrence doubling time, pathologic features
suggestive of a local recurrence (e.g., positive margins),
achievement or nonachievement of a nondetectable PSA
post-operatively, pattern of rise of PSA (whether or not
consistent with a local recurrence), long recurrence interval
from surgery, as well as patient factors [18, 20, 21].
3.ImagingintheSettingofBiochemicalRelapse
One of the major issues with local therapy (whether for
newly diagnosed clinically localized disease or in the setting
of BCR) is the lack of ability to accurately determine the
presence or absence of distant metastatic disease. It is likely
that the most signiﬁcant reason for failure of most attempts
at salvage therapy for biochemically recurrent PC is the
presence of undetected metastatic disease. Conventional
imaging techniques such as transrectal ultrasonography,
magnetic resonance imaging (MRI), computed tomographyAdvances in Urology 3
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Figure 1: Anterior (a) and posterior (b) planar gamma camera images of radiolabeled J591. A greater number of lesions are apparent
compared to anterior (c) and posterior (d) 99mTc-MDP bone scan. Hepatic clearance of radiolabeled mAb results in nonspeciﬁc uptake in
the liver.
(CT), and 99Tm-MDP scintigraphy (bone scan) are usually
not sensitive or speciﬁc enough to detect metastatic or
recurrent prostate disease [22–28]. Therefore, an increase in
PSA may precede a clinically detectable recurrent pelvic or
metastatic cancer by months to years [29].
Though initial attempts using monoclonal antibodies
(mAbs) to PSA and PAP were unsuccessful [30], more
recently various and more speciﬁc markers of PC have
been identiﬁed, including cell surface proteins, glycoprotein,
receptors, enzymes, and peptides [31]. Prostate-speciﬁc
membrane antigen (PSMA) is the most well established,
highly speciﬁc prostate epithelial cell membrane antigen
known [32–36] .T h eﬁ r s ta n do n l ya p p r o v e da g e n tf o r
targeting PSMA in PC is 111In-capromab [37].
An initial study utilizing capromab pendetide in men
BCR after prostatectomy and lymphadenectomy demon-
strated safety [38]. Kahn et al. performed a study in 32
men with BCR after prostatectomy prior to SRT; 61% of
those with evidence of local disease only had a durable
response to SRT versus 28% with durable response if they
had evidence of distant disease on 111In-capromab imaging
[39]. However, while additional similar studies support these
results [40], others have demonstrated no beneﬁt with the
use of capromab pendetide in selection of patients for local
salvage therapy [41, 42]. Some eﬀorts to improve 111In-
capromab imaging have added SPECT/CT fusion imaging,
but results remain suboptimal [43–45].
Amajorreasonforthesuboptimalresultswithcapromab
pendetide lies with its targeting of the internal domain of
PSMA, leading to the inability to bind to viable cells [32–
35, 46]. Recognition of these features led to the development
ofmAbsbyBanderetal.totheexposed,extracellulardomain
of PSMA [46–48]. J591, a deimmunized mAb against the
extracellular domain of PSMA, has been the lead clinical
candidate [48, 49]. While no formal prostate imaging studies
of J591 have been conducted, several therapeutic studies
examining the clinical utility of radiolabeled J591 have
been performed with built-in imaging components [49–51].
Radiolabeled J591 has successfully targeted (imaged) 89–
100% osseous targeting and 69–100% soft tissue targeting
[49–51], including cases where J591 demonstrated lesions
that were not apparent on the bone scan but were identiﬁed
on subsequent MR or conventional imaging as the lesion
progressed (Figure 1)[ 52]. Current imaging work with anti-
PSMA mAbs involves immune-PET imaging [53, 54]. Addi-
tional studies utilize small molecule inhibitors, including
123I-MIP-1072, 123I-MIP-1095, 99mTc-MIP-1404, and 99mTc-
MIP-1405 [55, 56].
4. Systemic Therapy for Biochemical Relapse
The addition of hormonal therapy to primary RT has
led to improvements for some men with clinically local-
ized PC, possibly by radiosensitization and/or treating
micrometastaticdisease.ThismightbetruewithSRTaswell,
with several retrospective studies supporting this concept
[57, 58]. Initial results of a large, prospective randomized
study, RTOG 9601, in which SRT was compared with SRT
+ bicalutamide in patients with an elevated PSA after prosta-
tectomy have been presented [57]. With a median followup
of seven years, a statistically signiﬁcant improvement in
freedom from PSA progression with adjuvant bicalutamide
versus RT alone has been reported (57 versus 40%) as well
as incidence of metastatic disease (7 versus 13%). RTOG
0534, a Phase III Trial of short-term androgen deprivation4 Advances in Urology
with pelvic lymph node or prostate bed only radiotherapy
(SPPORT) in PC patients with a rising PSA after RP, is
currently accruing (http://www.clinicaltrials.gov/ct2/show/
NCT00567580/). Patients are randomly assigned to one
of three arms: prostate bed RT only, prostate bed RT +
neoadjuvant and concurrent ADT, or RT to the prostate bed
and pelvic lymph nodes with neoadjuvant and concurrent
ADT [59]. This study will help address the utility of the
addition of ADT to SRT.
Though good local salvage options exist, not all patients
qualify or agree to receive them, and most suﬀer disease
progression despite local salvage therapy, likely because of
micrometastatic disease outside of the prostate/prostate bed
and pelvis that is not apparent on conventional imaging.
Therefore systemic therapy is often employed. The most
common management option for BCR after local therapy
is ADT. While many studies have demonstrated that ADT
does not prolong time to metastases and death in all comers,
there are subgroups that likely beneﬁt. Higher-grade disease
and poorer PSA kinetics (i.e., short PSA doubling time) may
predict improvement in outcome with early ADT [60, 61].
Additional evidence to support early ADT stems from the
high-riskclinicallylocalizedorlocallyadvancedsettings[62–
64]. However, while ADT may lead to some improvements,
toxicity exists [65–70], and it is not curative in this situation.
Chemotherapy is proven to improve survival and patient-
reported outcomes in late stage disease but, as in most
advanced solid tumors, is not able to overcome bulky disease
and leads to cures in that setting [71, 72]. The addition of
chemotherapy at an earlier stage has demonstrated a survival
beneﬁt in many solid tumors (i.e., neoadjuvant or adjuvant
chemotherapy in combination with surgery/radiotherapy),
presumably by eradicating micrometastatic sites of dis-
ease. We await the results of a study examining the use
of chemotherapy in combination with hormonal ther-
apy to treat micrometastatic disease in men with BCR
after prostatectomy (http://www.clinicaltrials.gov/ct2/show/
NCT00514917/)[ 73].
5. Prostate-SpeciﬁcMembrane Antigen-Based
Radioimmunotherapy
As discussed above, the concept of systemic therapy to elimi-
nate micrometastatic disease has merit. “Targeted therapy”
is designed to deliver agents to malignant cells and spare
normal cells. PSMA is an ideal target for prostate cancer,
based upon its near universal expression in PC. While the
initial observations were that expression was limited to
prostate cells, it is now known that there are low levels
of expression in other tissues, including brush border of
small intestine, renal proximal tubule lumen, and salivary
glands. However, levels of expression are greatly increased
in prostate cancer (as opposed to benign prostatic epithelial
cells) and increase with grade, stage, and hormonal therapy
[32–35]. Furthermore, alternative sites with low levels of
expression have minimal or no exposure to circulating
mAb, as they are protected by basement membranes and
their luminal surface site of expression. Several studies
have demonstrated the ability of radiolabeled J591 to target
and treat metastatic castration-resistant prostate cancer
(CRPC).
Two independent phase I radioimmunotherapy (RIT)
trials were performed using Yttrium-90 (90Y) or Lutetium-
177(177Lu)linkedviaaDOTAchelatetoJ591inpatientswith
metastatic CRPC. These trials deﬁned the MTD and further
reﬁned dosimetry, pharmacokinetics, and immunogenicity
(HAHA) of the radiolabeled mAb with some eﬃcacy seen
[50, 51]. Additional phase I and phase II studies utilizing
177Lu-J591 have conﬁrmed the ability of J591 to successfully
target various sites of metastatic prostate cancer with the
majority of subjects receiving full doses of radiolabeled
antibody experiencing PSA declines and some measurable
disease responses demonstrated [49, 74, 75]. As expected
with radioimmunotherapy in general, dose-limiting toxicity
is reversible myelosuppression, with a minority of patients
also experiencing mAb-related infusion reactions (without
pre-medication) or transient grade 1 transaminitis [49–51,
74–76].
Based on the physical properties of radionuclides, diﬀer-
ential responses are expected depending upon radionuclide
and tumor properties. 177Lu is a low energy β emitter best
for lesions 1–3mm in diameter, while the higher β energy
of 90Y is best suited for 28–42mm lesions [77]. An initial
review of J591 RIT validated these properties in the clinical
CRPC setting [76]. This leads to the hypothesis that 177Lu-
J591 should be less eﬀective in the bulky metastatic CRPC
setting but may lead to signiﬁcantly more beneﬁt in a
micrometastatic disease setting. Indeed, RIT in general may
have a higher impact in the minimal disease setting [78–80].
Prostate cancer is a radiosensitive disease, and BCR is
common. Salvage local therapy may be successful but does
not address disease sites outside of the prostate bed/pelvis,
and most patients ultimately progress. Nearly all PC over-
expressesPSMA;J591isabletotargetmetastaticdiseasesites.
Full length anti-PSMA mAb has minimal to no access to
other sites of low-level PSMA expression. Anti-PSMA-based
RIT has demonstrated eﬃcacy, and 177Lu is optimal for 1–
3mm (i.e., micrometastatic) lesions.
Enrollment is ongoing in a multicenter Department of
Defense and Prostate Cancer Foundation-sponsored study
testing the concept of salvage targeted anti-PSMA-based
RIT(http://www.clinicaltrials.gov/ct2/show/NCT00859781/).
Men with high-risk CRPC (PSA doubling time <8 months
and/orPSA>20[73])andnoevidenceofdiseaseonCT/MRI
and bone scans are randomized in a 2:1 fashion to receive
double-blinded 177Lu-J951 versus 111In-J591 (control) with
a backbone of hormonal therapy (ketoconazole and hydro-
cortisone) and will undergo planar gamma camera imaging
withSPECTfollowinginfusion.Theprimaryendpointofthe
study is 18-month metastasis-free survival with additional
endpoints ofmedian metastasis-freesurvivalandoverallsur-
vival.Secondary/exploratoryendpointsincludeevaluationof
radiolabeled J591 imaging to detect sites of metastases not
apparent on standard CT/MRI and bone scan, validation
of adrenal androgen levels as biomarkers for ketoconazole
[81], and analysis of circulating tumor cells captured via
CellSearch methodology as well as PSMA-GEDI capture [82]Advances in Urology 5
for PSMA expression and counts to predict the appearance
of radiographic metastases.
6. Conclusions
Biochemical relapse after local therapy for prostate cancer
is common. While local salvage therapy is available, deﬁ-
ciencies in imaging currently lead to diﬃculties in selecting
appropriate patients. For those with microscopic sites of
diseaseoutsideoftheprostate/prostatebed,targetedsystemic
salvage therapy is appealing. Prostate-speciﬁc membrane
antigen-based diagnostics and therapeutics may lead to
improvements in this disease setting.
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